May, 2023, Eutropics has entered an exploratory research agreement with Massachusetts General Brigham, a teaching hospital of Harvard Medical School, to support application of the PRIMABS™-Dx platform in tumors associated with Neurofibromatosis Type 1 (NF1). As part of this collaboration,…
In October 2025, a publication in the International Journal of Molecular Sciences (doi:10.3390/ijms26209859) described Eutropics’ PRIMABS™ conformation‑specific antibody platform, which directly measures BCL‑2 family protein–protein interactions to predict response to BH3‑mimetics. Independent research groups are now citing this work in…
2019 – AACR Annual Meeting (Atlanta)Eutropics presented a poster titled “Identifying Bcl-2 family protein dependencies in tumors using dimerization-specific antibody biomarkers as a method for predicting response to apoptosis-inducing therapies.” Eutropics 2018 – EHA23 (European Hematology Association)Data from a Phase…
September, 2018, Eutropics Pharmaceuticals has been selected for a prestigious NIH/NCI SBIR Phase IIB Bridge Award providing 3 million dollars in non‑dilutive matching funds tied to commercial revenues generated from its PraediCare functional precision oncology platform. This award is designed…
In June 2019, Eutropics Pharmaceuticals was awarded highly competitive funding from MassVentures’ SBIR Targeted Technologies (START) program to support the commercialization of its PraediCare Dx predictive cancer diagnostics platform. The non‑dilutive START Stage III grant builds on earlier Stage I…
September, 2024, Eutropics Pharmaceuticals is pleased to announce an extension of its long-standing research collaboration with the University of Texas MD Anderson Cancer Center, focused on advancing the PRIMAB™ functional biomarker platform in Acute Myeloid Leukemia (AML). The renewed MTA agreement…
December, 2024, in the United States, Eutropics and the Keck School of Medicine of the University of Southern California (USC) entered a research collaboration with the to evaluate its PRIMAB™ Dx diagnostic platform in Acute Myeloid Leukemia (AML). The study…
April, 2025, Eutropics Protein/Protein interaction detectors platform is published in “Cancers” DOI: 10.3390 In this We describe a new diagnostics platform based on a novel panel of antibody-based reagents that have significant research utility and potential clinical utility for the…
October, 2025, PRIMABS recent article in the International Journal of Molecular Sciences (doi:10.3390/ijms26209859) describes Eutropics’ PRIMAB conformation‑specific antibody platform, which directly measures BCL‑2 family protein–protein interactions to predict BH3‑mimetic response. Independent groups are now citing this work in the context…
March, 2026, In Singapore, Eutropics today announced a research collaboration with the National University of Singapore (NUS) to evaluate the company’s PRIMAB™ functional biomarker platform in Multiple Myeloma. The partnership will explore how PRIMAB’s predictive insights into tumor cell apoptosis…